How to cite item

Targeting cancer with PI3K pathway inhibitors: who to aim at?

   
@article{TCR382,
	author = {Kathryn M. Kinross and Karen E. Sheppard and Richard B. Pearson and Wayne A. Phillips},
	title = {Targeting cancer with PI3K pathway inhibitors: who to aim at?},
	journal = {Translational Cancer Research},
	volume = {1},
	number = {2},
	year = {2012},
	keywords = {},
	abstract = {Breast and gynecological (ovarian, endometrial and cervical) cancers commonly harbor mutations activating the PI3K pathway, including PIK3CA mutation/amplification, PTEN loss or HER2 amplification. Insight from the successful development of many targeted cancer therapeutics suggests that these tumor types with a high prevalence of mutations in the PI3K pathway would be ideal candidates for therapy with inhibitors of that pathway. This was indeed the case with imatinib to target Bcr-Abl positive CML patients and cKIT mutant GIST tumors; vemurafenib to target B-RAFV600E melanoma; trastuzumab to target HER2 positive breast cancer; and crizotinib to target EML4-ALK positive lung tumors.},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/382}
}